<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099486</url>
  </required_header>
  <id_info>
    <org_study_id>GI-094</org_study_id>
    <nct_id>NCT03099486</nct_id>
  </id_info>
  <brief_title>Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC</brief_title>
  <official_title>A Pilot Phase II, Single Arm, Open Label, Investigator-initiated Clinical Trial of Regorafenib Plus 5-Fluorouracil/Leucovorin (5FU/LV) Beyond Progression on Regorafenib Monotherapy in Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion&#xD;
      in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU&#xD;
      containing chemotherapy combinations.The study will enroll mCRC patients with prior&#xD;
      progression on standard multi-agent combination chemotherapy and progression on regorafenib&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Administrative change&#xD;
  </why_stopped>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">October 22, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) at 2 months</measure>
    <time_frame>2 months</time_frame>
    <description>PFS at 2 months in mCRC patients who progress on regorafenib monotherapy and are treated with regorafenib and 5-FU/LV combination therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 years</time_frame>
    <description>Overall survival will be calculated from the day of first treatment until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>1-2 years</time_frame>
    <description>This will be calculated from the day of first treatment dose until disease progression or death, whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of toxicities due to regorafenib and 5-FU/LV combination therapy</measure>
    <time_frame>1-2 years</time_frame>
    <description>Number of toxicities due to combination therapy will be summarized by frequencies and grades of toxicities due to the combination therapy according to CTCAE 4.03 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Regorafenib + 5FU/LV Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.</description>
    <arm_group_label>Regorafenib + 5FU/LV Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours</description>
    <arm_group_label>Regorafenib + 5FU/LV Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,</description>
    <arm_group_label>Regorafenib + 5FU/LV Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. mCRC with prior progression on standard multi-agent combination chemotherapy and&#xD;
             regorafenib as a standard approved monotherapy. Progression on prior regorafenib is&#xD;
             required for inclusion in this clinical study. Prior regimens may include FOLFOX -/+&#xD;
             bevacizumab, FOLFIRI -/+ bevacizumab or -/+ cetuximab (if KRAS wild-type) or&#xD;
             panitumumab (if KRAS wilt-type). Other prior regimens may include 5-FU or capecitabine&#xD;
             -/+ bevacizumab, irinotecan -/+ cetuximab or panitumumab, FOLFIRI -/+ ziv-aflibercept&#xD;
             or ramucirumab.&#xD;
&#xD;
          2. Patients treated with oxaliplatin in an adjuvant setting should have progressed during&#xD;
             or within 6 months of completion of adjuvant therapy. Patients who progress more than&#xD;
             6 months after completion of oxaliplatin containing adjuvant treatment must be&#xD;
             retreated. Patients who have withdrawn from standard treatment due to unacceptable&#xD;
             toxicity warranting discontinuation of treatment and precluding retreatment with the&#xD;
             same agent prior to progression of disease will also be allowed in the study.&#xD;
&#xD;
          3. Patients previously treated with chemotherapy must have at least 4 weeks period&#xD;
             between the last dose of previous chemotherapy and the first dose in this clinical&#xD;
             study. Patients previously treated with biologics such as Avastin, Zaltrap, Erbitux,&#xD;
             and Vectibix must have at least 6 weeks period between the last dose of previous&#xD;
             chemotherapy and the first dose in this clinical study.&#xD;
&#xD;
          4. Measurable metastatic disease that is refractory.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          6. Patients are included regardless of KRAS/NRAS, BRAF, p53, or microsatellite&#xD;
             instability (MSI) status&#xD;
&#xD;
          7. Age ≥ 18 years.&#xD;
&#xD;
          8. Life expectancy of at least 8 weeks (2 months).&#xD;
&#xD;
          9. Subjects must be able to understand and be willing to sign the written informed&#xD;
             consent form. A signed informed consent form must be appropriately obtained prior to&#xD;
             the conduct of any trial-specific procedure.&#xD;
&#xD;
         10. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x the upper limits of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN&#xD;
                  (≤ 5 x ULN for subjects with liver involvement of their cancer)&#xD;
&#xD;
               -  Alkaline phosphatase limit ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver&#xD;
                  involvement of their cancer)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x the ULN&#xD;
&#xD;
               -  International normalized ratio (INR)/ Partial thromboplastin time (PTT) ≤ 1.5 x&#xD;
                  ULN.&#xD;
&#xD;
               -  Platelet count &gt; 100000 /mm3, hemoglobin (Hb) &gt; 9 g/dL, absolute neutrophil count&#xD;
                  (ANC) ≥ 1500/mm3. Blood transfusion to meet the inclusion criteria will not be&#xD;
                  allowed.&#xD;
&#xD;
         11. Subject must be able to swallow and retain oral medication.&#xD;
&#xD;
         12. Up to 5 of the 15 patients will be allowed to have had other approved or&#xD;
             investigational drugs after prior progression of Regorafenib monotherapy. (all&#xD;
             patients enrolled in this trial must have had prior progression on regorafenib&#xD;
             therapy). This may include TAS102, off-label therapy that may have been prescribed&#xD;
             based on tumor genomic profiling or any investigational agents on a clinical trial.&#xD;
&#xD;
         13. No more than grade 2 toxicity with last previous cycle of regorafenib mono therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving any concurrent investigational agents&#xD;
&#xD;
          2. Previous assignment to treatment during this study. Subjects permanently withdrawn&#xD;
             from study participation will not be allowed to re-enter study.&#xD;
&#xD;
          3. Uncontrolled hypertension (systolic pressure &gt;140 mm Hg or diastolic pressure &gt; 90 mm&#xD;
             Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management.&#xD;
&#xD;
          4. Active or clinically significant cardiac disease including:&#xD;
&#xD;
               -  Congestive heart failure - New York Heart Association (NYHA) &gt; Class II.&#xD;
&#xD;
               -  Active coronary artery disease.&#xD;
&#xD;
               -  Suspected Long QT syndrome defined as QTc interval &gt; 500 milliseconds at&#xD;
                  baseline.&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or&#xD;
                  digoxin.&#xD;
&#xD;
               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months&#xD;
                  before randomization, or myocardial infarction within 6 months before&#xD;
                  randomization.&#xD;
&#xD;
          5. Evidence or history of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          6. Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of&#xD;
             study medication.&#xD;
&#xD;
          7. Subjects diagnosed with thrombotic, embolic, venous, or arterial events, such as&#xD;
             cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis&#xD;
             or pulmonary embolism within 3 months of start of study treatment.&#xD;
&#xD;
          8. Patients with any previously untreated or concurrent cancer that is distinct in&#xD;
             primary site or histology except cervical cancer in-situ, treated ductal carcinoma in&#xD;
             situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive&#xD;
             aerodigestive neoplasms, or superficial bladder tumor. Subjects surviving a cancer&#xD;
             that was curatively treated and without evidence of disease for more than 3 years&#xD;
             before registration are allowed; all cancer treatments must be completed at least 3&#xD;
             years prior to registration.&#xD;
&#xD;
          9. Patients with phaeochromocytoma.&#xD;
&#xD;
         10. Known history of human immunodeficiency virus (HIV) infection or current chronic or&#xD;
             active hepatitis B or C infection requiring treatment with antiviral therapy.&#xD;
&#xD;
         11. Ongoing infection &gt; Grade 2 NCI-CTCAE v4.0.&#xD;
&#xD;
         12. Symptomatic metastatic brain or meningeal tumors.&#xD;
&#xD;
         13. Presence of a non-healing wound, non-healing ulcer, or bone fracture.&#xD;
&#xD;
         14. Major surgical procedure or significant traumatic injury within 28 days before start&#xD;
             of study medication&#xD;
&#xD;
         15. Renal failure requiring hemo-or peritoneal dialysis.&#xD;
&#xD;
         16. Dehydration Grade ≥1 NCI-CTCAE v4.0.&#xD;
&#xD;
         17. Patients with seizure disorder requiring medication.&#xD;
&#xD;
         18. Persistent proteinuria ≥ Grade 3 per NCI-CTCAE v4.0 (&gt; 3.5 g/24 hrs, measured by urine&#xD;
             protein: creatinine ratio on a random urine sample).&#xD;
&#xD;
         19. Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent.&#xD;
&#xD;
         20. Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version&#xD;
             4.0 Grade 2 dyspnea).&#xD;
&#xD;
         21. History of organ allograft (including corneal transplant).&#xD;
&#xD;
         22. Known or suspected allergy or hypersensitivity to any of the study drugs, study drug&#xD;
             classes, or excipients of the formulations given during the course of this trial.&#xD;
&#xD;
         23. Any malabsorption condition.&#xD;
&#xD;
         24. Women who are pregnant or breast-feeding.&#xD;
&#xD;
         25. Any condition which, in the investigator's opinion, makes the subject unsuitable for&#xD;
             trial participation.&#xD;
&#xD;
         26. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results.&#xD;
&#xD;
         27. Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) or with&#xD;
             heparins and heparinoids.&#xD;
&#xD;
             a. However, prophylactic anticoagulation as described below is allowed: i. Low dose&#xD;
             warfarin (1 mg orally, once daily) with PT-INR ≤ 1.5 x ULN is permitted.&#xD;
&#xD;
             ii. Low dose aspirin (≤ 100 mg daily). iii. Prophylactic doses of heparin. iv. Low&#xD;
             molecular weight heparin Subjects who are prophylactically treated with an agent such&#xD;
             as warfarin or heparin require close monitoring (day5 of cycle 1 and day 1 of each&#xD;
             cycle) of their INR/PTT. If either of these values are above the therapeutic range,&#xD;
             the doses should be modified and the assessments should be repeated weekly until they&#xD;
             are stable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namrata Vijayvergia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03099486/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>August 24, 2021</submitted>
    <returned>September 17, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

